Glycostem Therapeutics BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glycostem.com
Clinical Trials
5
Active:3
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)Registry of Patients Having Received oNKord®
Recruiting
- Conditions
- AML
- Interventions
- Drug: oNKord®Drug: Cyclophosphamide/Fludarabine (Cy/Flu)
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Glycostem Therapeutics BV
- Target Recruit Count
- 50
- Registration Number
- NCT05290662
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇨🇭University Hospital Basel, Basel, Switzerland
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Phase 1
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Cyclophosphamide-Fludarabine (Cy/Flu)Drug: oNKord®
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Glycostem Therapeutics BV
- Target Recruit Count
- 33
- Registration Number
- NCT04632316
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
🇧🇪University Hospital Leuven, Leuven, Belgium
🇫🇷Institut Gustave Roussy, Villejuif, France
News
No news found